Find a Doctor

Yael P. Mossé, MD

Attending Physician

Assistant Professor, Perelman School of Medicine at the University of Pennsylvania

Abstracts

2009

Wood A, Laudenslager M, Haglund EA, Attiyeh EF, Cole KA, Diskin S, et al. Potent Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF02341066 [abstract]. 2009 ASCO Annual Meeting; Orlando, FL, 2009 May 30-Jun 3.

Awards

2012, ASCO Junior Faculty Award in Pediatric Oncology
2010-2013, Department of Defense Award
2009-2014, R01 NIH/NCI
2006-2007, CHOP Foerderer-Murray Award
2005-2010, KO8 NIH Mentored Research Career Award
2004-2007, Career Development Award, American Society of Clinical Oncology
2003, Young Investigator Grant Recipient, Caitlin Robb Foundation
2003, Young Investigator Award, American Society of Clinical Oncology
2000, Selected Participant, American Association for Cancer Research Workshop, Molecular Biology in Clinical Oncology, The Given Institute, Aspen, CO
1996, Outstanding Medical Student Award, Sackler School of Medicine

Editorial and Academic Positions

Reviewer for journals

Gene
Cancer Genetics Cytogenetics
Oncogene
Journal of Clinical Oncology
Medical and Pediatric Oncology
Neoplasia
Pediatric Blood and Cancer
Cancer Research 

Academic committees

University of Pennsylvania

2008, Full member, Abramson Cancer Center of the University of Pennsylvania

The Children's Hospital of Philadelphia

2008, Member, Clinical Research Quality Assurance Committee
2008, Member, Institutional Review Board
2006, Member, Genes Genomes and Pediatric Diseases Research Affinity Group

Leadership

Memberships in professional organizations

American Association for Cancer Research
American Society of Clinical Oncology
Children's Oncology Group

Participation in scientific committees

International scientific committees

International Neuroblastoma Research Committee

National scientific committees

2009-present, Chair, COG ADVL0912 (PF-02341066) Phase 1/2 protocol, 2009-, Institutional PI, New Approaches to Neuroblastoma Therapy (NANT) Phase 1 Consortium
2008-present, Chair, COG ADVL0812 (MLN8237) Phase 1/2 protocol
2007-present, COG ANBL07P1 Study Committee
2006-present, Chair, COG Neuroblastoma Adolescent Task Force
2005-present, COG Neuroblastoma Biology Subcommittee
2005-present, COG Neuroblastoma Phase II Working Group
2004-present, member, Neuroblastoma Strategy Group, Children’s Oncology Group (COG) 

Original Papers

2011

Devoto M, Specchia C, Laudenslager M, Longo L, Hakonarson H, Maris J, et al. Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma. Hum Hered. 2011;71(2):135-9. Epub 2011 Jul 6. Cited in PubMed: PMID 21734404. Read the abstract 

Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris JM, et al. Safety and efficacy of tandem (131) I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer. Epub 2011 Apr 14. doi: 10.1002/pbc.23062. Cited in PubMed: PMID 21495159. Read the abstract

Nguyen le B, Diskin SJ, Capasso M, Wang K, Diamond MA, Glessner J, et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility loci. PLoS Genet. 2011 Mar;7(3)e1002026. Epub 2011 Mar 17. Cited in PubMed: PMID 21436895. Read the article

Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3336-41. Epub 2011 Feb 2. Cited in PubMed: PMID 21289283. Read the abstract

Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, et al Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011 Jan 13;469(7329):216-20. Epub 2010 Dec 1. Read the abstract 

2010

Lipsitz E, Moorthy G, Mosse Y, Fox E, Adamson PC. A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma. J Chromatorgr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2369-73. Epub 2010 Jul 3. Cited in PubMed: PMID 20685183. Read the abstract

Yu D, dos Santos CO, Zhao G, Jiang J, Amigo JD, Khandros E, et al. miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta. Genes Dev. 2010 Aug 1;24(15):1620-33. Cited in PubMed: PMID 20679398. Read the article

2009

Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 2009 Jun 18;459(7249):987-91. Cited in PubMed: PMID 19536264. Read the article 

Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009 Jun;41(6):718-23. Epub 2009 May 3. Cited in PubMed: PMID 19412175.  Read the article

Attiyeh EF, Diskin SJ, Attiyeh MA, Mossé YP, Hou C, Jackson EM, et al. Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. Genome Res. 2009 Feb;19(2):276-83. Epub 2009 Jan 13. Erratum in: Genome Res. 2009 Mar;19(3):520. Cited in PubMed: PMID 19141597. Read the article

« Back to Previous Page
  • Print
  • Share

Contact Us